# Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors

> **NCT05598151** · PHASE1 · RECRUITING · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 170 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** HM97662

## Key facts

- **NCT ID:** NCT05598151
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-11
- **Primary completion:** 2028-01
- **Final completion:** 2028-06
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05598151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05598151, "Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05598151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*